CareDx (NASDAQ:CDNA – Get Free Report) was upgraded by equities researchers at Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Thursday,Zacks.com reports. William Blair upgraded CareDx to a “hold” rating in a research report on Thursday, July 16th. Wall Street Zen upgraded shares of CareDx from a “buy” rating to a “strong-buy” rating in a research report on Sunday, May 3rd. Get CareDx alerts:Get Our Latest Stock Report on CareDxCareDx Price PerformanceShares of CareDx stock opened at $46.69 on Thursday. CareDx Company Profile(Get Free Report)CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients.